Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis

Multiple Sclerosis

Volumn 14, Issue 8, 2008, Pages 1068-1075

  Furby, J ^a   Hayton, T ^a   Anderson, V ^a   Altmann, D ^b   Brenner, R ^c   Chataway, J ^d   Hughes, R A C ^e   Smith, K J ^a   Miller, D H ^a   Kapoor, R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atrophy; Disability; MRI; Multiple sclerosis; Secondary progressive multiple sclerosis

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN REGION; BRAIN SIZE; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE MARKER; EXPANDED DISABILITY STATUS SCALE; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; NUCLEAR MAGNETIC RESONANCE IMAGING; RATING SCALE; SCORING SYSTEM; SPINAL CORD ATROPHY; WHITE MATTER; BRAIN; CROSS-SECTIONAL STUDY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REFERENCE VALUE; SPINAL CORD;

ADULT; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; REFERENCE VALUES; SPINAL CORD;

EID: 58149359335     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508093617     Document Type: Article

References (43)

1. Smith, KJ, McDonald, I, Miller, D, Lassmann, H. The pathophysiology of multiple sclerosis. In: Compston, A, Confavreux, C, Lassmann, H, et al. (eds). McAlpine's Multiple Sclerosis. London: Churchill Livingstone; 2006. p. 601-659.
2. Losseff, NA, Wang, L, Lau, HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119: 2009-2019.
3. De Stefano, N, Matthews, PM, Fu, L, et al. Axonal damage correlates with disability in patients with relapsing remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-1477.
4. Bjartmar, C, Kidd, G, Mork, S, Rudick, R, Trapp, BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893-901.
5. IFNB Multiple Scelerosis Study Group. Interferon beta 1b is effective in relapsing remittingmultiple sclerosis. I. Clinical results of a multicenter, randomized, double blind placebocontrolled trial. Neurology 1993; 43: 655-661.
6. Edan, G, Miller, D, Clanet, M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
7. Polman, CH, O'Connor, PW, Havrdova, E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
8. Kappos, L, Moeri, D, Radue, EW, et al. Predictive value of gadolinium enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis. Lancet 1999; 353: 964-969.
9. Kalkers, NF, Bergers, L, Castelijns, JA, et al. Optimizing the association between disability and biological markers of MS. Neurology 2001; 57: 1253-1258.
10. Li, DK, Held, U, Petkau, J, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology 2006; 66: 1384-1389.
11. Fisher, E, Rudick, RA, Simon, JH, et al. Eight-year follow-up study of brain atrophy in patients withMS. Neurology 2002; 59: 1412-1420.
12. Miller, DH. Biomarkers and Surrogate Outcomes in Neurodegenerative Disease: Lessons from multiple sclerosis. NeuroRx 2004; 1: 284-294.
13. Truyen, L, van Waesberghe, JH, vanWalderveen, MA, et al. Accumulation of hypointense (black holes) on T1 spinecho MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469-1476.
14. Filippi, M, Rovaris, M, Inglese, M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.
15. Anderson, VM, Fox, NC, Miller, DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006; 23: 605-618.
16. Dalton, CM, Chard, DT, Davies, GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004; 127: 1101-1107.
17. Sanfilipo, MP, Benedict, RHB, Sharma, J, Weinstock-Guttman, B, Bakshi, R. The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005; 26: 1068-1077.
18. Tiberio, M, Chard, DT, Altmann, DR, et al. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study. Neurology 2005; 64: 1001-1007.
19. De Stefano, N, Matthews, PM, Filippi, M, et al. Evidence of early cortical atrophy in MS: Relevance to white matter changes and disability. Neurology 2003; 60: 1157-1162.
20. Zivadinov, R, Locatelli, L, Cookfair, D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing- remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007; 13: 490-501.
21. Molyneux, PD, Kappos, L, Polman, C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000; 123: 2256-2263.
22. Stevenson, VL, Smith, SM, Matthews, PM, Miller, DH, Thompson, AJ. Monitoring disease progression and activity in primary progressive multiple sclerosis using MRI: Sub-voxel registration to identify lesion changes and to detect cerebral atrophy. J Neurol 2002; 249: 171-177.
23. Losseff, NA, Webb, SL, O'Riordan, JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119: 701-708.
24. Lin, X, Blumhardt, LD, Constantinescu, CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: A three dimensional study. Acta Neurol Scand 2003; 108: 401-406.
25. Sastre-Garriga, J, Ingel, GT, Rovaris, M, et al. Long term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. Neurology 2005; 65: 633-635.
26. Furby, J, Hayton, T, Smith, KJ, et al. [abstract] A randomised controlled trial of neuroprotection with lamotrigine in secondary progressive multiple sclerosis. Mult Scler 2006; 12: S228.
27. Smith, SM, Zhang, Y, Jenkinson, M, et al. Accurate, robust and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
28. Freeborough, PA, Fox, NC, Kitney, RI. Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Comput Methods Programs Biomed 1997; 53: 15-25.
29. Cutter, GR, Baier, ML, Rudick, RA, et al. Development of the multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
30. Bermel, RA, Sharma, J, Tjoa, CW, Puli, SR, Bakshi, R. A semi-automated measure of whole brain atrophy in multiple scelrosis. J Neurol Sci 2003; 208: 57-65.
31. Evangelou, N, Esiri, M, Smith, S, Palace, J, Matthews, PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47: 391-395.
32. Kutzelnigg, A, Lucchinetti, CF, Stadelmann, C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
33. Peterson, JW, Bo, L, Mork, S, Chang, A, Trapp, BD. Transected neurites, apoptotic neurons and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389-400.
34. Chard, DT, Griffin, CM, Rashid, W, et al. Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 387-391.
35. Tedeschi, G, Lavorgna, L, Russo, P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280-285.
36. Sastre-Garriga, J, Ingle, GT, Chard, DT, Ramio-Torrenta, L, Miller, DH, Thompson, AJ. Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis. Neuroimage 2004; 22: 353-359.
37. Houtchens, MK, Benedict, RH, Killiany, R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007; 69: 1213-1223.
38. Ashburner, J, Friston, K. Multimodal image coregistration and partitioning-a unified framework. Neuroimage 1997; 6: 209-217.
39. Comi, G, Fillippi, M, Martinelli, V, et al. Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995; 132: 222-227.
40. Amato, MP, Zipoli, V, Portaccio, E. Multiple sclerosisrelated cognitive changes: A review of cross-sectional and longitudinal studies. J Neurol Sci 2006; 245: 41-46.
41. Morgen, K, Sammer, G, Courtney, SM, et al. Evidence for a direct association between cortical atrophy and cognitive impairment in relapsing-remitting MS. Neuroimage 2006; 30: 891-898.
42. Sanfilpo, MP, Benedict, RH, Weinstock-Guttman, B, Bakshi, R. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006; 66: 685-692.
43. Hobart, J, Kalkers, N, Barkhof, F, Uitdehaag, B, Polman, C, Thompson, A. Outcome measures for multiple sclerosis clinical trials: Relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 41-46.